

ALLERGAN INC
Form 4
March 19, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hindman James M.

(Last) (First) (Middle)

2525 DUPONT DRIVE

(Street)

IRVINE, CA 92612

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

ALLERGAN INC [AGN]

3. Date of Earliest Transaction
(Month/Day/Year)

03/17/2015

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director _____ 10% Owner
____X____ Officer (give title _____ Other (specify
below) below)

EVP, Finance & Bus. Dev., CFO

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/16/2015		G	V 2,174	D \$ 0 21,046.636	D	
Common Stock	03/17/2015		A	11,273.669 (1)	A \$ 0 32,320.305	D	
Common Stock	03/17/2015		D	32,320.305 (2)	D (2) 0	D	
Common Stock	03/17/2015		D	6,495.2496 (2)	D (2) 0	I	By 401(k)
Common Stock	03/17/2015		D	6,044.7258 (2)	D (2) 0	I	By ESOP

Edgar Filing: ALLERGAN INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Security (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount Owned Number Shares
Employee Stock Option (Right to Buy)	\$ 55.98	03/17/2015		D	18,000	<u>(3)</u>	02/06/2016	Common Stock	18,000
Employee Stock Option (Right to Buy)	\$ 58.55	03/17/2015		D	19,000	<u>(3)</u>	02/02/2017	Common Stock	19,000
Employee Stock Option (Right to Buy)	\$ 64.47	03/17/2015		D	17,600	<u>(3)</u>	02/14/2018	Common Stock	17,600
Employee Stock Option (Right to Buy)	\$ 40.16	03/17/2015		D	22,300	<u>(3)</u>	02/20/2019	Common Stock	22,300
Employee Stock Option (Right to Buy)	\$ 59.13	03/17/2015		D	18,950	<u>(3)</u>	02/22/2020	Common Stock	18,950
Employee Stock Option (Right to Buy)	\$ 75.58	03/17/2015		D	19,000	<u>(3)</u>	02/17/2021	Common Stock	19,000

Employee Stock Option (Right to Buy)	\$ 87.91	03/17/2015	D	15,500	<u>(3)</u>	02/17/2022	Common Stock	13
Employee Stock Option (Right to Buy)	\$ 105.87	03/17/2015	D	14,000	<u>(3)</u>	02/21/2023	Common Stock	14
Employee Stock Option (Right to Buy)	\$ 105.87	03/17/2015	D	1,000	<u>(3)</u>	02/21/2023	Common Stock	1
Employee Stock Option (Right to Buy)	\$ 125.07	03/17/2015	D	12,057	<u>(3)</u>	02/21/2024	Common Stock	12
Restricted Stock Units	<u>(4)</u>	03/17/2015	D	11,273.669	<u>(4)</u>	10/29/2024	Common Stock	11,2
Restricted Stock Units	<u>(5)</u>	03/17/2015	D	511	<u>(5)</u>	<u>(5)</u>	Common Stock	

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hindman James M. 2525 DUPONT DRIVE IRVINE, CA 92612			EVP, Finance & Bus. Dev., CFO	

Signatures

/s/ Matthew J. Maletta, attorney-in-fact for James M.
Hindman

03/18/2015

 Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents 11,271 performance-based restricted stock units granted on October 29, 2014 and 2.699 dividend equivalent rights acquired
(1) with respect to each vested restricted stock unit (collectively, the "RSUs"). The RSUs vested in full on the Effective Date pursuant to the terms of the Merger Agreement (each as defined below).

Edgar Filing: ALLERGAN INC - Form 4

- Pursuant to that certain Agreement and Plan of Merger dated November 16, 2014, (the "Merger Agreement") by and among the Issuer, Actavis, Plc ("Actavis") and a wholly-owned subsidiary of Actavis, the Issuer became an indirect wholly-owned subsidiary of Actavis upon consummation of the merger (the "Effective Date"). Each share of common stock was disposed of in exchange for \$129.22 cash plus 0.3683 of an Actavis ordinary share, having a market value of \$307.51 per share on the Effective Date.
- (2)

- Each option vested in full on the Effective Date and was cancelled in exchange for a cash payment equal to the number of shares subject to the option immediately prior to the merger, multiplied by the difference between (i) 0.3683 times \$294.1509 (which represents the 10-day volume weighted average price of Actavis stock starting on the 11th trading day prior to the closing) plus \$129.22 and (ii) the exercise price of the option, subject to the applicable withholding taxes and pursuant to the procedures set forth in the merger.
- (3)

- Represents 11,271 restricted stock units and 2.669 dividend equivalent rights acquired with respect to each vested stock units. The restricted stock units ("RSUs") vested in full on the Effective Date and each RSU was cancelled in exchange for 0.3638 shares of Actavis stock having a market value of \$307.51 per shares, on the Effective Date, and \$129.22 in cash.
- (4)

- The restricted stock units ("RSUs") vested in full on the Effective Date and each RSU was cancelled in exchange for 0.3683 shares of Actavis stock having a market value of \$307.51 per share on the Effective Date, and \$129.22 in cash.
- (5)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.